BOT

2.63%

37.0¢ botanix pharmaceuticals ltd

Ann: BTX 1702 Rosacea Study Approval, page-59

First 59 Last

Share
Profile

Follow
dachopper

4,195 Posts.

5493

31/03/21

15:29

Post #: 52177515
Share

Originally posted by triage: ↑

Hi Deadlifts - I would think safety and tolerance are exactly the primary endpoints you would expect from a Phase 1a trial. I think more to the point is what concentrations of CBD they will be testing. As some poster quite insightfully suggested the other week, the company already knows that at 5% and 10% concentrations CBD is safe and tolerable but maybe, for the benefit of the acne product as much as this product, they want to see what happens if they bump the concentration up to 15% or 20%. I can't see in this announcement what the two levels of concentration will be but I suspect that other poster was spot on.

If this trial shows that at say 20% CBD the product is safe and tolerable, even if it does not prove a clear winner when it comes to rosacea - and in no way am I saying it won't be shown to have an effect - they can use the primary endpoint success here on whatever they decide to do with the acne product's development. That, I would guess, is why they are holding off on the next step of the acne product development until they get the results of this trial.

The other point I picked up is that this is a very robustly constructed trial. I think there was some frustration that in the antimicrobial resistance trial the patients were not required to do a wash like apparently was required in other similar trials. It would have been an easy enough extra step but without it Botanix could not show how good the results were. Also, I'm not sure where the stuff up in the previous acne trial was but the US results in that trial again muddied what they could say. So, a big tick for this trial being robustly designed.

Expand

They have allready tested it much higher, I think they said 20 or 30% in a previous trial without issues.

BOT Price at posting: 9.7¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 43 more messages in this thread...

First 59 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 37.0¢		Change -0.010(2.63%)		Mkt cap ! $671.1M

Open	High	Low	Value	Volume
38.0¢	38.0¢	37.0¢	$1.949M	5.207M

Buyers (Bids)

No.	Vol.	Price($)
7	163455	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	33207	2

View Market Depth

No.	Vol.	Price($)
4	130837	0.370
10	99517	0.365
16	271384	0.360
7	220353	0.355
26	1051912	0.350

Price($)	Vol.	No.
0.380	44778	1
0.385	245000	3
0.390	10960	1
0.395	123443	3
0.400	179748	4

Last trade - 16.10pm 04/10/2024 (20 minute delay)

BOT (ASX) Chart

Ann: BTX 1702 Rosacea Study Approval, page-59

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: BTX 1702 Rosacea Study Approval, page-59

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News